Erratum: Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly (BioMed Research International (2014) 2014 (169203) DOI: 10.1155/2014/169203);Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Arosio, Beatrice ^a,b   D'Addario, Claudio ^c,d   Gussago, Cristina ^b   Casati, Martina ^a   Tedone, Enzo ^b   Ferri, Evelyn ^b   Nicolini, Paola ^a   Rossi, Paolo D ^a   Maccarrone, Mauro ^e,f   Mari, Daniela ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF TERAMO   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

^e IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^f UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; BIOLOGICAL MARKER; PEPTIDYLPROLYL ISOMERASE PIN1;

ALZHEIMER DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EPIGENETICS; HUMAN; INFLAMMATION; LABORATORY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; AGED; BLOOD; CENTRAL NERVOUS SYSTEM; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MONITORING, PHYSIOLOGIC;

EID: 84901326342     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2020/9175369     Document Type: Erratum

References (163)

1. Barnes D. E., Yaffe K., The projected effect of risk factor reduction on Alzheimer's disease prevalence. The Lancet Neurology 2011 10 9 819 828 2-s2.0-80051669619 10.1016/S1474-4422(11)70072-2
2. Gorelick P. B., Scuteri A., Black S. E., Decarli C., Greenberg S. M., Iadecola C., Launer L. J., Laurent S., Lopez O. L., Nyenhuis D., Petersen R. C., Schneider J. A., Tzourio C., Arnett D. K., Bennett D. A., Chui H. C., Higashida R. T., Lindquist R., Nilsson P. M., Roman G. C., Sellke F. W., Seshadri S., Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011 42 9 2672 2713 2-s2.0-80052400687 10.1161/STR. 0b013e3182299496
3. Fratiglioni L., Launer L. J., Andersen K., Breteler M. M. B., Copeland J. R. M., Dartigues J.-F., Lobo A., Martinez-Lage J., Soininen H., Hofman A., Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 2000 54 supplement 11 S10 S15 2-s2.0-18244428862 (Pubitemid 30390599)
4. Battistin L., Cagnin A., Vascular cognitive disorder. A biological and clinical overview. Neurochemical Research 2010 35 12 1933 1938 2-s2.0-78651301462 10.1007/s11064-010-0346-5
5. Jellinger K. A., The enigma of vascular cognitive disorder and vascular dementia. Acta Neuropathologica 2007 113 4 349 388 2-s2.0-33947282799 10.1007/s00401-006-0185-2 (Pubitemid 46421627)
6. Iadecola C., Neurovascular regulation in the normal brain and in Alzheimer's disease. Nature Reviews Neuroscience 2004 5 5 347 360 2-s2.0-2342614850 (Pubitemid 38568496)
7. Zlokovic B. V., New therapeutic targets in the neurovascular pathway in Alzheimer's disease. Neurotherapeutics 2008 5 3 409 414 2-s2.0-46749099351 10.1016/j.nurt.2008.05.011 (Pubitemid 351952489)
8. Atkinson J., Colburn W. A., DeGruttola V. G., DeMets D. L., Downing G. J., Hoth D. F., Oates J. A., Peck C. C., Schooley R. T., Spilker B. A., Woodcock J., Zeger S. L., Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 2001 69 3 89 95 2-s2.0-0035100888 10.1067/mcp.2001.113989 (Pubitemid 32225406)
9. Tardif J.-C., Heinonen T., Orloff D., Libby P., Vascular biomarkers and surrogates in cardiovascular disease. Circulation 2006 113 25 2936 2942 2-s2.0-33747132177 10.1161/CIRCULATIONAHA.105.598987 (Pubitemid 44297235)
10. Puntmann V. O., How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgraduate Medical Journal 2009 85 1008 538 545 2-s2.0-70349664473 10.1136/pgmj.2008.073759
11. Wade A., Derivation versus validation. Archives of Disease in Childhood 2000 83 6 459 460 2-s2.0-0033635329 10.1136/adc.83.6.459
12. Lausted C., Lee I., Zhou Y., Qin S., Sung J., Price N. D., Hood L., Wang K., Systems approach to neurodegenerative disease biomarker discovery. Annual Review of Pharmacology and Toxicology 2014 54 457 481
13. McKhann G., Drachman D., Folstein M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984 34 7 939 944 2-s2.0-0021271971 (Pubitemid 14076461)
14. Dubois B., Feldman H. H., Jacova C., DeKosky S. T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P. J., Scheltens P., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. The Lancet Neurology 2007 6 8 734 746 2-s2.0-34447322271 10.1016/S1474-4422(07)70178-3 (Pubitemid 47058377)
15. Wiltfang J., Esselmann H., Bibl M., Hüll M., Hampel H., Kessler H., Frölich L., Schröder J., Peters O., Jessen F., Luckhaus C., Perneczky R., Jahn H., Fiszer M., Maler J. M., Zimmermann R., Bruckmoser R., Kornhuber J., Lewczuk P., Amyloid β peptide ratio 42/40 but not A β 42 correlates with phospho-Tau in patients with low- and high-CSF A β 40 load. Journal of Neurochemistry 2007 101 4 1053 1059 2-s2.0-34247581358 10.1111/j.1471-4159. 2006.04404.x (Pubitemid 46683864)
16. Farias G., Perez P., Slachevsky A., Maccioni R. B., Platelet tau pattern correlates with cognitive status in Alzheimer's disease. Journal of Alzheimer's Disease 2012 31 1 65 69
17. Neumann K., Farías G., Slachevsky A., Perez P., MacCioni R. B., Human platelets tau: a potential peripheral marker for Alzheimer's disease. Journal of Alzheimer's Disease 2011 25 1 103 109 2-s2.0-79959650192 10.3233/JAD-2011-101641
18. Hooper C., Lovestone S., Sainz-Fuertes R., Alzheimer's disease, diagnosis and the need for biomarkers. Biomarker Insights 2008 2008 3 317 323 2-s2.0-45749109439 (Pubitemid 351865648)
19. Petersen R. C., Smith G. E., Waring S. C., Ivnik R. J., Tangalos E. G., Kokmen E., Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology 1999 56 3 303 308 2-s2.0-0032988610 (Pubitemid 29120227)
20. Simmons A., Westman E., Muehlboeck S., Mecocci P., Vellas B., Tsolaki M., Kåoszewska I., Wahlund L.-O., Soininen H., Lovestone S., Evans A., Spenger C., The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. International Journal of Geriatric Psychiatry 2011 26 1 75 82 2-s2.0-78650392746 10.1002/gps.2491
21. de Leon M. J., Desanti S., Zinkowski R., Mehta P. D., Pratico D., Segal S., Clark C., Kerkman D., Debernardis J., Li J., Lair L., Reisberg B., Tsui W., Rusinek H., MRI and CSF studies in the early diagnosis of Alzheimer's disease. Journal of Internal Medicine 2004 256 3 205 223 2-s2.0-4544306699 10.1111/j.1365-2796.2004.01381.x (Pubitemid 39222990)
22. Hampel H., Bürger K., Teipel S. J., Bokde A. L. W., Zetterberg H., Blennow K., Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimer's and Dementia 2008 4 1 38 48 2-s2.0-38049179307 10.1016/j.jalz.2007.08.006
23. Craig-Schapiro R., Fagan A. M., Holtzman D. M., Biomarkers of Alzheimer's disease. Neurobiology of Disease 2009 35 2 128 140 2-s2.0-67649531853 10.1016/j.nbd.2008.10.003
24. Morris J. C., Roe C. M., Grant E. A., Head D., Storandt M., Goate A. M., Fagan A. M., Holtzman D. M., Mintun M. A., Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Archives of Neurology 2009 66 12 1469 1475 2-s2.0-73549092137 10.1001/archneurol.2009.269
25. Perrin R. J., Fagan A. M., Holtzman D. M., Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009 461 7266 916 922 2-s2.0-70350061949 10.1038/nature08538
26. Maddalena A., Papassotiropoulos A., Müller-Tillmanns B., Jung H. H., Hegi T., Nitsch R. M., Hock C., Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β -amyloid peptide42. Archives of Neurology 2003 60 9 1202 1206 2-s2.0-0042972779 10.1001/archneur.60.9.1202 (Pubitemid 37099624)
27. de Meyer G., Shapiro F., Vanderstichele H., Vanmechelen E., Engelborghs S., De Deyn P. P., Coart E., Hansson O., Minthon L., Zetterberg H., Blennow K., Shaw L., Trojanowski J. Q., Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Archives of Neurology 2010 67 8 949 956 2-s2.0-77955453909 10.1001/archneurol.2010.179
28. Visser P. J., Verhey F., Knol D. L., Scheltens P., Wahlund L.-O., Freund-Levi Y., Tsolaki M., Minthon L., Wallin Å. K., Hampel H., Bürger K., Pirttila T., Soininen H., Rikkert M. O., Verbeek M. M., Spiru L., Blennow K., Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. The Lancet Neurology 2009 8 7 619 627 2-s2.0-67649628753 10.1016/S1474-4422(09) 70139-5
29. Ingelson M., Blomberg M., Benedikz E., Wahlund L.-O., Karlsson E., Vanmechelen E., Lannfelt L., Tau immunoreactivity detected in human plasma, but no obvious increase in dementia. Dementia and Geriatric Cognitive Disorders 1999 10 6 442 445 2-s2.0-0032731573 10.1159/000017187 (Pubitemid 29512009)
30. Mattsson N., Roseń E., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.-K., Van Der Flier W. M., Blankenstein M. A., Ewers M., Rich K., Kaiser E., Verbeek M. M., Olde Rikkert M., Tsolaki M., Mulugeta E., Aarsland D., Visser P. J., Schroder J., Marcusson J., De Leon M., Hampel H., Scheltens P., Wallin A., Eriksdotter-Jonhagen M., Minthon L., Winblad B., Blennow K., Zetterberg H., Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 2012 78 7 468 476 2-s2.0-84858113047 10.1212/WNL.0b013e3182477eed
31. Schoonenboom N. S. M., Reesink F. E., Verwey N. A., Kester M. I., Teunissen C. E., Van De Ven P. M., Pijnenburg Y. A. L., Blankenstein M. A., Rozemuller A. J., Scheltens P., van der Flier W. M., Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012 78 1 47 54 2-s2.0-84856617005 10.1212/WNL.0b013e31823ed0f0
32. Hüll M., Lieb K., Fiebich B. L., Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Current Medicinal Chemistry 2002 9 1 83 88 2-s2.0-0036230270 (Pubitemid 34436451)
33. McGeer E. G., McGeer P. L., Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Molecular Interventions 2001 1 1 22 29 2-s2.0-2342558048
34. McGeer E. G., McGeer P. L., Chronic inflammation in Alzheimer's disease offers therapeutic opportunities. Expert Review of Neurotherapeutics 2001 1 1 53 60 2-s2.0-0035741377 10.1586/14737175.1.1.53 (Pubitemid 34627368)
35. Licastro F., Chiappelli M., Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background. Mechanisms of Ageing and Development 2003 124 4 539 548 2-s2.0-0037396305 10.1016/S0047-6374(03)00034-4 (Pubitemid 36514911)
36. Rogers J., Lue L.-F., Microglial chemotaxis, activation, and phagocytosis of amyloid β -peptide as linked phenomena in Alzheimer's disease. Neurochemistry International 2001 39 5-6 333 340 2-s2.0-0034814056 10.1016/S0197-0186(01)00040-7 (Pubitemid 32907397)
37. Szczepanik A. M., Funes S., Petko W., Ringheim G. E., IL-4, IL-10 and IL-13 modulate A β (1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. Journal of Neuroimmunology 2001 113 1 49 62 2-s2.0-0035255055 10.1016/S0165-5728(00)00404-5 (Pubitemid 32008670)
38. Chao C. C., Molitor T. W., Hu S., Neuroprotective role of IL-4 against activated microglia. Journal of Immunology 1993 151 3 1473 1481 2-s2.0-0027197996 (Pubitemid 23219285)
39. Arosio B., Trabattoni D., Galimberti L., Bucciarelli P., Fasano F., Calabresi C., Cazzullo C. L., Vergani C., Annoni G., Clerici M., Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiology of Aging 2004 25 8 1009 1015 2-s2.0-2942755836 10.1016/j. neurobiolaging.2003.10.009 (Pubitemid 38798062)
40. Tuppo E. E., Arias H. R., The role of inflammation in Alzheimer's disease. International Journal of Biochemistry and Cell Biology 2005 37 2 289 305 2-s2.0-4944258716 10.1016/j.biocel.2004.07.009 (Pubitemid 39330191)
41. Holmes C., Butchart J., Systemic inflammation and Alzheimer's disease. Biochemical Society Transactions 2011 39 4 898 901 2-s2.0-79960887486 10.1042/BST0390898
42. McGeer P. L., McGeer E. G., NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiology of Aging 2007 28 5 639 647 2-s2.0-33847339301 10.1016/j.neurobiolaging.2006.03.013 (Pubitemid 46349357)
43. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H. L., Hooper C., Rijsdijk F., Tabrizi S. J., Banner S., Shaw C. E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R. G., Sham P., Ward M., Lovestone S., Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006 129, part 11 3042 3050 2-s2.0-33750596715 10.1093/brain/awl279 (Pubitemid 44684524)
44. Begley D. J., Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacology and Therapeutics 2004 104 1 29 45 2-s2.0-6944255523 10.1016/j.pharmthera.2004.08.001 (Pubitemid 39410561)
45. Guerreiro R. J., Santana I., Brás J. M., Santiago B., Paiva A., Oliveira C., Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment. Neurodegenerative Diseases 2007 4 6 406 412 2-s2.0-35048877702 10.1159/000107700 (Pubitemid 47557281)
46. Tan Z. S., Beiser A. S., Vasan R. S., Roubenoff R., Dinarello C. A., Harris T. B., Benjamin E. J., Au R., Kiel D. P., Wolf P. A., Seshadri S., Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology 2007 68 22 1902 1908 2-s2.0-34249784822 10.1212/01.wnl.0000263217. 36439.da (Pubitemid 46848622)
47. Rudrabhatla P., Pant H. C., Phosphorylation-specific peptidyl-prolyl isomerization of neuronal cytoskeletal proteins by pin1: implications for therapeutics in neurodegeneration. Journal of Alzheimer's Disease 2010 19 2 389 403 2-s2.0-77049096276 10.3233/JAD-2010-1243
48. Wulf G., Finn G., Suizu F., Lu K. P., Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nature Cell Biology 2005 7 5 435 441 2-s2.0-18344387559 10.1038/ncb0505-435 (Pubitemid 40637396)
49. Lu P.-J., Zhou X. Z., Liou Y.-C., Noel J. P., Lu K. P., Critical role of WW domain phosphorylation in regulating phosphoserine binding activity and Pin1 function. Journal of Biological Chemistry 2002 277 4 2381 2384 2-s2.0-0037169479 10.1074/jbc.C100228200 (Pubitemid 34953258)
50. Pastorino L., Ma S. L., Balastik M., Huang P., Pandya D., Nicholson L., Lu K. P., Alzheimer's disease-related loss of Pin1 function influences the intracellular localization and the processing of AbetaPP. Journal of Alzheimer's Disease 2012 30 2 277 297
51. Zhou X. Z., Kops O., Werner A., Lu P.-J., Shen M., Stoller G., Küllertz G., Stark M., Fischer G., Lu K. P., Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and Tau proteins. Molecular Cell 2000 6 4 873 883 2-s2.0-0033638180
52. Galas M.-C., Dourlen P., Bégard S., Ando K., Blum D., Hamdane M., Buée L., The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons: implication in a pathological mechanism related to Alzheimer disease. Journal of Biological Chemistry 2006 281 28 19296 19304 2-s2.0-33745819942 10.1074/jbc.M601849200 (Pubitemid 44035434)
53. Hamdane M., Dourlen P., Bretteville A., Sambo A.-V., Ferreira S., Ando K., Kerdraon O., Bégard S., Geay L., Lippens G., Sergeant N., Delacourte A., Maurage C.-A., Galas M.-C., Buée L., Pin1 allows for differential Tau dephosphorylation in neuronal cells. Molecular and Cellular Neuroscience 2006 32 1-2 155 160 2-s2.0-33745095542 10.1016/j.mcn.2006.03.006 (Pubitemid 43884983)
54. Liou Y.-C., Sun A., Ryo A., Zhou X. Z., Yu Z.-X., Huang H.-K., Uchida T., Bronson R., Bing G., Li X., Hunter T., Lu K. P., Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 2003 424 6948 556 561 2-s2.0-0043069764 10.1038/nature01832 (Pubitemid 36975777)
55. Lu P.-J., Wulf G., Zhou X. Z., Davies P., Lu K. P., The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 1999 399 6738 784 788 2-s2.0-0033600242 10.1038/21650 (Pubitemid 29293174)
56. Pastorino L., Sun A., Lu P. J., Zhou X. Z., Balastik M., Finn G., Wulf G., Lim J., Li S. H., Li X., Xia W., Nicholson L. K., Lu K. P., The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006 440 7083 528 534
57. Butterfield D. A., Abdul H. M., Opii W., Newman S. F., Joshi G., Ansari M. A., Sultana R., Pin1 in Alzheimer's disease. Journal of Neurochemistry 2006 98 6 1697 1706 2-s2.0-33748029809 10.1111/j.1471-4159.2006.03995.x (Pubitemid 44298238)
58. Sultana R., Boyd-Kimball D., Poon H. F., Cai J., Pierce W. M., Klein J. B., Markesbery W. R., Zhou X. Z., Lu K. P., Butterfield D. A., Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiology of Aging 2006 27 7 918 925 2-s2.0-33646511135 10.1016/j.neurobiolaging.2005.05.005
59. Dakson A., Yokota O., Esiri M., Bigio E. H., Horan M., Pendleton N., Richardson A., Neary D., Snowden J. S., Robinson A., Davidson Y. S., Mann D. M. A., Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimer's disease pathology and is independent of tau, A β and TDP-43 pathology. Acta Neuropathologica 2011 121 5 635 649 2-s2.0-79958153883 10.1007/s00401-011-0798-y
60. Holzer M., Gärtner U., Stöbe A., Härtig W., Gruschka H., Brücker M. K., Arendt T., Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus. Acta Neuropathologica 2002 104 5 471 481 2-s2.0-0036938198 (Pubitemid 36075415)
61. Ramakrishnan P., Dickson D. W., Davies P., Pin1 colocalization with phosphorylated tau in Alzheimer's disease and other tauopathies. Neurobiology of Disease 2003 14 2 251 564 2-s2.0-0142157635 10.1016/S0969-9961(03)00109-8 (Pubitemid 37311289)
62. Thorpe J. R., Morley S. J., Rulten S. L., Utilizing the peptidyl-prolyl cis-trans isomerase Pin1 as a probe of its phosphorylated target proteins: examples of binding to nuclear proteins in a human kidney cell line and to tau in Alzheimer's diseased brain. Journal of Histochemistry and Cytochemistry 2001 49 1 97 108 2-s2.0-0035177565
63. Thorpe J. R., Mosaheb S., Hashemzadeh-Bonehi L., Cairns N. J., Kay J. E., Morley S. J., Rulten S. L., Shortfalls in the peptidyl-prolyl cis-trans isomerase protein Pin1 in neurons are associated with frontotemporal dementias. Neurobiology of Disease 2004 17 2 237 249 2-s2.0-5144224351 10.1016/j.nbd.2004. 07.008 (Pubitemid 39345779)
64. Segat L., Pontillo A., Annoni G., Trabattoni D., Vergani C., Clerici M., Arosio B., Crovella S., PIN1 promoter polymorphisms are associated with Alzheimer's disease. Neurobiology of Aging 2007 28 1 69 74 2-s2.0-33751327516 10.1016/j.neurobiolaging.2005.11.009 (Pubitemid 44802916)
65. Butterfield D. A., Poon H. F., St. Clair D., Keller J. N., Pierce W. M., Klein J. B., Markesbery W. R., Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiology of Disease 2006 22 2 223 232 2-s2.0-33646144212 10.1016/j.nbd.2005.11.002
66. Arosio B., Bulbarelli A., Bastias Candia S., Lonati E., Mastronardi L., Romualdi P., Candeletti S., Gussago C., Galimberti D., Scarpini E., Dell'Osso B., Altamura C., MacCarrone M., Bergamaschini L., D'Addario C., Mari D., Pin1 contribution to Alzheimer's disease: transcriptional and epigenetic mechanisms in patients with late-onset Alzheimer's disease. Neurodegenerative Diseases 2012 10 1-4 207 211 2-s2.0-84860214307 10.1159/000333799
67. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L. F., Galasko D. R., Jutel M., Karydas A., Kaye J. A., Leszek J., Miller B. L., Minthon L., Quinn J. F., Rabinovici G. D., Robinson W. H., Sabbagh M. N., So Y. T., Sparks D. L., Tabaton M., Tinklenberg J., Yesavage J. A., Tibshirani R., Wyss-Coray T., Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Medicine 2007 13 11 1359 1362 2-s2.0-35948933394 10.1038/nm1653 (Pubitemid 350073592)
68. Gavin D. P., Sharma R. P., Histone modifications, DNA methylation, and Schizophrenia. Neuroscience and Biobehavioral Reviews 2010 34 6 882 888 2-s2.0-77950627166 10.1016/j.neubiorev.2009.10.010
69. Ando K., Dourlen P., Sambo A. V., Bretteville A., Belarbi K., Vingtdeux V., Eddarkaoui S., Drobecq H., Ghestem A., Begard S., Demey-Thomas E., Melnyk P., Smet C., Lippens G., Maurage C. A., Caillet-Boudin M. L., Verdier Y., Vinh J., Landrieu I., Galas M. C., Blum D., Hamdane M., Sergeant N., Buee L., Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. Neurobiology of Aging 2013 34 3 757 769
70. Wang S., Simon B. P., Bennett D. A., Schneider J. A., Malter J. S., Wang D.-S., The significance of Pin1 in the development of Alzheimer's disease. Journal of Alzheimer's Disease 2007 11 1 13 23 2-s2.0-33847755982 (Pubitemid 46376706)
71. Maruszak A., Safranow K., Gustaw K., Kijanowska-Haładyna B., Jakubowska K., Olszewska M., Styczyńska M., Berdyński M., Tysarowski A., Chlubek D., Siedlecki J., Barcikowska M., Zekanowski C., PIN1 gene variants in Alzheimer's disease. BMC Medical Genetics 2009 10, article 115 2-s2.0-73349130451
72. Storace D., Cammarata S., Borghi R., Sanguineti R., Giliberto L., Piccini A., Pollero V., Novello C., Caltagirone C., Smith M. A., Bossù P., Perry G., Odetti P., Tabaton M., Elevation of β -amyloid 1-42 autoantibodies in the blood of amnestic patients with mild cognitive impairment. Archives of Neurology 2010 67 7 867 872 2-s2.0-77955024322 10.1001/archneurol.2010.137
73. Bulbarelli A., Lonati E., Cazzaniga E., Gregori M., Masserini M., Pin1 affects Tau phosphorylation in response to A β oligomers. Molecular and Cellular Neuroscience 2009 42 1 75 80 2-s2.0-67651004680 10.1016/j.mcn.2009.06. 001
74. Lonati E., Masserini M., Bulbarelli A., Pin1: a new outlook in alzheimer's disease. Current Alzheimer Research 2011 8 6 615 622 2-s2.0-80051722674 10.2174/156720511796717140
75. Bakulski K. M., Rozek L. S., Dolinoy D. C., Paulson H. L., Hu H., Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics. Current Alzheimer Research 2012 9 5 563 573
76. Pidsley R., Mill J., Epigenetic studies of psychosis: current findings, methodological approaches, and implications for postmortem research. Biological Psychiatry 2011 69 2 146 156 2-s2.0-78650429158 10.1016/j.biopsych.2010.03.029
77. Morris K. V., The emerging role of RNA in the regulation of gene transcription in human cells. Seminars in Cell and Developmental Biology 2011 22 4 351 358 2-s2.0-80051884378 10.1016/j.semcdb.2011.02.017
78. Gidlöf O., Andersson P., van der Pals J., Götberg M., Erlinge D., Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 2011 118 4 217 226 2-s2.0-79959419859 10.1159/000328869
79. Kuwabara Y., Ono K., Horie T., Nishi H., Nagao K., Kinoshita M., Watanabe S., Baba O., Kojima Y., Shizuta S., Imai M., Tamura T., Kita T., Kimura T., Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circulation: Cardiovascular Genetics 2011 4 4 446 454 2-s2.0-80052760391 10.1161/CIRCGENETICS.110.958975
80. Mitchell P. S., Parkin R. K., Kroh E. M., Fritz B. R., Wyman S. K., Pogosova-Agadjanyan E. L., Peterson A., Noteboom J., O'Briant K. C., Allen A., Lin D. W., Urban N., Drescher C. W., Knudsen B. S., Stirewalt D. L., Gentleman R., Vessella R. L., Nelson P. S., Martin D. B., Tewari M., Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 2008 105 30 10513 10518 2-s2.0-48749122914 10.1073/pnas.0804549105
81. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., Hood L. E., Galas D. J., Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proceedings of the National Academy of Sciences of the United States of America 2009 106 11 4402 4407 2-s2.0-63149121152 10.1073/pnas. 0813371106
82. Jones P. A., Taylor S. M., Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980 20 1 85 93 2-s2.0-0018860957 (Pubitemid 10117303)
83. Feinberg A. P., Irizarry R. A., Stochastic epigenetic variation as a driving force of development, evolutionary adaptation, and disease. Proceedings of the National Academy of Sciences of the United States of America 2010 107 supplement 1 1757 1764 2-s2.0-76549135113 10.1073/pnas.0906183107
84. Fraga M. F., Esteller M., Epigenetics and aging: the targets and the marks. Trends in Genetics 2007 23 8 413 418 2-s2.0-34447625911 10.1016/j.tig.2007.05.008 (Pubitemid 47088010)
85. Bjornsson H. T., Sigurdsson M. I., Fallin M. D., Irizarry R. A., Aspelund T., Cui H., Yu W., Rongione M. A., Ekström T. J., Harris T. B., Launer L. J., Eiriksdottir G., Leppert M. F., Sapienza C., Gudnason V., Feinberg A. P., Intra-individual change over time in DNA methylation with familial clustering. Journal of the American Medical Association 2008 299 24 2877 2883 2-s2.0-45849127657 10.1001/jama.299.24.2877 (Pubitemid 351930887)
86. Gentilini D., Mari D., Castaldi D., Remondini D., Ogliari G., Ostan R., Bucci L., Sirchia S. M., Tabano S., Cavagnini F., Monti D., Franceschi C., di Blasio A. M., Vitale G., Role of epigenetics in human aging and longevity: genome-wide DNA methylation profile in centenarians and centenarians' offspring. Age 2013 35 5 1961 1973
87. Esteller M., Molecular origins of cancer: epigenetics in cancer. The New England Journal of Medicine 2008 358 11 1148 1059 2-s2.0-40849139208 10.1056/NEJMra072067 (Pubitemid 351398489)
88. Horike S.-I., Cai S., Miyano M., Cheng J.-F., Kohwi-Shigematsu T., Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nature Genetics 2005 37 1 31 40 2-s2.0-11244328520 10.1038/ng1491 (Pubitemid 40070937)
89. DeBaun M. R., Niemitz E. L., McNeil D. E., Brandenburg S. A., Lee M. P., Feinberg A. P., Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects. The American Journal of Human Genetics 2002 70 3 604 611 2-s2.0-0036182963 10.1086/338934 (Pubitemid 34177916)
90. Faulk C., Dolinoy D. C., Timing is everything: the when and how of environmentally induced changes in the epigenome of animals. Epigenetics 2011 6 7 791 797 2-s2.0-79960148707 10.4161/epi.6.7.16209
91. Barker D. J. P., The developmental origins of chronic adult disease. Acta Paediatrica, Supplement 2004 93 446 26 33 2-s2.0-10844241534 10.1080/08035320410022730 (Pubitemid 39664526)
92. Hanson M., Godfrey K. M., Lillycrop K. A., Burdge G. C., Gluckman P. D., Developmental plasticity and developmental origins of non-communicable disease: theoretical considerations and epigenetic mechanisms. Progress in Biophysics and Molecular Biology 2011 106 1 272 280 2-s2.0-79957990635 10.1016/j.pbiomolbio. 2010.12.008
93. Wadhwa P. D., Buss C., Entringer S., Swanson J. M., Developmental origins of health and disease: brief history of the approach and current focus on epigenetic mechanisms. Seminars in Reproductive Medicine 2009 27 5 358 368 2-s2.0-69349095789 10.1055/s-0029-1237424
94. Jablonka E., Epigenetic epidemiology. International Journal of Epidemiology 2004 33 5 929 935 2-s2.0-7244258925 10.1093/ije/dyh231 (Pubitemid 39429982)
95. Calvanese V., Lara E., Kahn A., Fraga M. F., The role of epigenetics in aging and age-related diseases. Ageing Research Reviews 2009 8 4 268 276 2-s2.0-68149100569 10.1016/j.arr.2009.03.004
96. Fraga M. F., Genetic and epigenetic regulation of aging. Current Opinion in Immunology 2009 21 4 446 453 2-s2.0-68149183508 10.1016/j.coi.2009.04.003
97. D'Addario C., Dell'Osso B., Palazzo M. C., Benatti B., Lietti L., Cattaneo E., Galimberti D., Fenoglio C., Cortini F., Scarpini E., Arosio B., Di Francesco A., Di Benedetto M., Romualdi P., Candeletti S., Mari D., Bergamaschini L., Bresolin N., Maccarrone M., Altamura A. C., Selective DNA methylation of BDNF promoter in bipolar disorder: differences among patients with BDI and BDII. Neuropsychopharmacology 2012 37 7 1647 1655 2-s2.0-84857127877 10.1038/npp.2012.10
98. Sananbenesi F., Fischer A., The epigenetic bottleneck of neurodegenerative and psychiatric diseases. Biological Chemistry 2009 390 11 1145 1153 2-s2.0-70349798896 10.1515/BC.2009.131
99. Urdinguio R. G., Sanchez-Mut J. V., Esteller M., Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies. The Lancet Neurology 2009 8 11 1056 1072 2-s2.0-70449725209 10.1016/S1474-4422(09)70262-5
100. Chouliaras L., Rutten B. P. F., Kenis G., Peerbooms O., Visser P. J., Verhey F., van Os J., Steinbusch H. W. M., van den Hove D. L. A., Epigenetic regulation in the pathophysiology of Alzheimer's disease. Progress in Neurobiology 2010 90 4 498 510 2-s2.0-77950866465 10.1016/j.pneurobio.2010.01. 002
101. Mastroeni D., Grover A., Delvaux E., Whiteside C., Coleman P. D., Rogers J., Epigenetic mechanisms in Alzheimer's disease. Neurobiology of Aging 2011 32 7 1161 1180 2-s2.0-79958769568 10.1016/j.neurobiolaging.2010.08.017
102. Mill J., Toward an integrated genetic and epigenetic approach to Alzheimer's disease. Neurobiology of Aging 2011 32 7 1188 1191 2-s2.0-79958766982 10.1016/j.neurobiolaging.2010.10.021
103. Barrachina M., Ferrer I., DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. Journal of Neuropathology and Experimental Neurology 2009 68 8 880 891 2-s2.0-69449086451 10.1097/NEN. 0b013e3181af2e46
104. Tohgi H., Utsugisawa K., Nagane Y., Yoshimura M., Genda Y., Ukitsu M., Reduction with age in methylcytosine in the promoter region -224-101 of the amyloid precursor protein gene in autopsy human cortex. Molecular Brain Research 1999 70 2 288 292 2-s2.0-0033052929 10.1016/S0169-328X(99)00163-1 (Pubitemid 29317643)
105. Tohgi H., Utsugisawa K., Nagane Y., Yoshimura M., Ukitsu M., Genda Y., The methylation status of cytosines in a τ gene promoter region alters with age to downregulate transcriptional activity in human cerebral cortex. Neuroscience Letters 1999 275 2 89 92 2-s2.0-0032716797 10.1016/S0304-3940(99) 00731-4 (Pubitemid 29502543)
106. Mastroeni D., Grover A., Delvaux E., Whiteside C., Coleman P. D., Rogers J., Epigenetic changes in Alzheimer's disease: decrements in DNA methylation. Neurobiology of Aging 2010 31 12 2025 2037 2-s2.0-78650179659 10.1016/j.neurobiolaging.2008.12.005
107. Mastroeni D., McKee A., Grover A., Rogers J., Coleman P. D., Epigenetic differences in cortical neurons from a pair of monozygotic twins discordant for Alzheimer's disease. PLoS ONE 2009 4 8 2-s2.0-68949096744 10.1371/journal.pone. 0006617 e6617
108. Nunez-Iglesias J., Liu C.-C., Morgan T. E., Finch C. E., Zhou X. J., Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation. PloS ONE 2010 5 2 e8898 2-s2.0-77953312769 10.1371/journal.pone.0008898
109. Ogawa O., Zhu X., Lee H.-G., Raina A., Obrenovich M. E., Bowser R., Ghanbari H. A., Castellani R. J., Perry G., Smith M. A., Ectopic localization of phosphorylated histone H3 in Alzheimer's disease: a mitotic catastrophe? Acta Neuropathologica 2003 105 5 524 528 2-s2.0-0038388955 (Pubitemid 36798850)
110. Fuso A., Seminara L., Cavallaro R. A., D'Anselmi F., Scarpa S., S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Molecular and Cellular Neuroscience 2005 28 1 195 204 2-s2.0-10644237168 10.1016/j.mcn.2004.09.007 (Pubitemid 39656023)
111. Belakavadi M., Dell J., Grover G. J., Fondell J. D., Thyroid hormone suppression of β -amyloid precursor protein gene expression in the brain involves multiple epigenetic regulatory events. Molecular and Cellular Endocrinology 2011 339 1-2 72 80 2-s2.0-79958066914 10.1016/j.mce.2011.03.016
112. Dangond F., Gullans S. R., Differential expression of human histone deacetylase mRNAs in response to immune cell apoptosis induction by Trichostatin A and butyrate. Biochemical and Biophysical Research Communications 1998 247 3 833 837 2-s2.0-0032577868 10.1006/bbrc.1998.8891 (Pubitemid 28418477)
113. de Ruijter A. J. M., van Gennip A. H., Caron H. N., Kemp S., van Kuilenburg A. B. P., Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemical Journal 2003 370, part 3 737 749 2-s2.0-0037444803 10.1042/BJ20021321 (Pubitemid 36399066)
114. di Francesco A., Arosio B., Gussago C., Dainese E., Mari D., 'Addario C D., Maccarrone M., Involvement of 5-lipoxygenase in Alzheimer's disease: a role for DNA methylation. Journal of Alzheimer's Disease 2013 37 1 3 8
115. D'Addario C., Di Francesco A., Arosio B., Gussago C., Dell'Osso B., Bari M., Galimberti D., Scarpini E., Altamura A. C., Mari D., Maccarrone M.,
116. van der Stelt M., van Kuik J. A., Bari M., Van Zadelhoff G., Leeflang B. R., Veldink G. A., Finazzi-Agrò A., Vliegenthart J. F. G., Maccarrone M., Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase. Journal of Medicinal Chemistry 2002 45 17 3709 3720 2-s2.0-0037103365 10.1021/jm020818q (Pubitemid 34856111)
117. Rouzer C. A., Marnett L. J., Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chemical Reviews 2011 111 10 5899 5921 2-s2.0-80054080661 10.1021/cr2002799
118. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. Journal of Neuroscience 2003 23 35 11136 11141 2-s2.0-0348010292 (Pubitemid 37548949)
119. Cunningham C., Skelly D. T., Non-steroidal anti-inflammatory drugs and cognitive function: are prostaglandins at the heart of cognitive impairment in dementia and delirium? Journal of NeuroImmune Pharmacology 2012 7 1 60 73
120. Imbimbo B. P., Solfrizzi V., Panza F., Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Frontiers in Aging Neuroscience 2010 10.3389/fnagi.2010.00019
121. Ng S. C., Chan F. K., NSAID-induced gastrointestinal and cardiovascular injury. Current Opinion in Gastroenterology 2010 26 6 611 617
122. Petot G. J., Friedland R. P., Lipids, diet and Alzheimer disease: an extended summary. Journal of the Neurological Sciences 2004 226 1-2 31 33 2-s2.0-8644250557 10.1016/j.jns.2004.09.007 (Pubitemid 39505401)
123. Mendonça A., Cunha R. A., Therapeutic opportunities for caffeine in Alzheimer's disease and other neurodegenerative disorders. Journal of Alzheimer's Disease 2010 20 supplement 1 S1 S2 2-s2.0-77956222935 10.3233/JAD-2010-01420
124. Arendash G. W., Schleif W., Rezai-Zadeh K., Jackson E. K., Zacharia L. C., Cracchiolo J. R., Shippy D., Tan J., Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β -amyloid production. Neuroscience 2006 142 4 941 952 2-s2.0-33750984544 10.1016/j.neuroscience.2006. 07.021 (Pubitemid 44740473)
125. 1 receptors. Journal of Pharmacology and Experimental Therapeutics 1995 273 2 637 642 2-s2.0-0029077075
126. Dall'Igna O. P., Fett P., Gomes M. W., Souza D. O., Cunha R. A., Lara D. R., Caffeine and adenosine A 2 A receptor antagonists prevent β -amyloid (25-35)-induced cognitive deficits in mice. Experimental Neurology 2007 203 1 241 245 2-s2.0-33751427701 10.1016/j.expneurol.2006.08.008 (Pubitemid 44821181)
127. Johnson-Kozlow M., Kritz-Silverstein D., Barrett-Connor E., Morton D., Coffee consumption and cognitive function among older adults. The American Journal of Epidemiology 2002 156 9 842 850 2-s2.0-0036840451 10.1093/aje/kwf119 (Pubitemid 35215765)
128. van Boxtel M. P. J., Schmitt J. A. J., Bosma H., Jolles J., The effects of habitual caffeine use on cognitive change: a longitudinal perspective. Pharmacology Biochemistry and Behavior 2003 75 4 921 927 2-s2.0-0142106479 10.1016/S0091-3057(03)00171-0 (Pubitemid 37289479)
129. Fredholm B. B., Bättig K., Holmén J., Nehlig A., Zvartau E. E., Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacological Reviews 1999 51 1 83 133 2-s2.0-0345561561 (Pubitemid 29113867)
130. Haskó G., Linden J., Cronstein B., Pacher P., Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nature Reviews Drug Discovery 2008 7 9 759 770 2-s2.0-51049101334 10.1038/nrd2638
131. Headrick J. P., Ashton K. J., Rose'meyer R. B., Peart J. N., Cardiovascular adenosine receptors: expression, actions and interactions. Pharmacology & Therapeutics 2013 140 1 92 111
132. Fredholm B. B., Chern Y., Franco R., Sitkovsky M., Aspects of the general biology of adenosine A 2 A signaling. Progress in Neurobiology 2007 83 5 263 276 2-s2.0-34250703015 10.1016/j.pneurobio.2007.07.005 (Pubitemid 350102746)
133. Linden J., Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annual Review of Pharmacology and Toxicology 2001 41 775 787 2-s2.0-0035040532 10.1146/annurev.pharmtox.41.1.775 (Pubitemid 32385906)
134. Sebastião A. M., Ribeiro J. A., Tuning and fine-tuning of synapses with adenosine. Current Neuropharmacology 2009 7 3 180 194 2-s2.0-70349655666 10.2174/157015909789152128
135. Cronstein B. N., Kramer S. B., Rosenstein E. D., Weissmann G., Hirschhorn R., Adenosine modulates the generation of superoxide anion by stimulated human neutrophils via interaction with a specific cell surface receptor. Annals of the New York Academy of Sciences 1985 451 291 301 2-s2.0-0022272766 (Pubitemid 16199069)
136. Koshiba M., Kojima H., Huang S., Apasov S., Sitkovsky M. V., Memory of extracellular adenosine A 2 A purinergic receptor-mediated signaling in murine T cells. Journal of Biological Chemistry 1997 272 41 25881 25889 2-s2.0-0030803163 10.1074/jbc.272.41.25881 (Pubitemid 27438913)
137. Sitkovsky M., Lukashev D., Regulation of immune cells by local-tissue oxygen tension: HIF1 α and adenosine receptors. Nature Reviews Immunology 2005 5 9 712 721 2-s2.0-25444454359 10.1038/nri1685 (Pubitemid 43086172)
138. Chen J.-F., Sonsalla P. K., Pedata F., Melani A., Domenici M. R., Popoli P., Geiger J., Lopes L. V., de Mendonça A., Adenosine A 2 A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Progress in Neurobiology 2007 83 5 310 331 2-s2.0-36249032646 10.1016/j.pneurobio.2007.09.002 (Pubitemid 350119825)
139. Rodrigues R. J., Canas P. M., Lopes L. V., Oliveira C. R., Cunha R. A., Modification of adenosine modulation of acetylcholine release in the hippocampus of aged rats. Neurobiology of Aging 2008 29 10 1597 1601 2-s2.0-49349116847 10.1016/j.neurobiolaging.2007.03.025
140. Sitkovsky M. V., Use of the A 2 A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochemical Pharmacology 2003 65 4 493 501 2-s2.0-0037441343 10.1016/S0006-2952(02)01548-4 (Pubitemid 36144234)
141. Sitkovsky M. V., Lukashev D., Apasov S., Kojima H., Koshiba M., Caldwell C., Ohta A., Thiel M., Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A 2 A receptors. Annual Review of Immunology 2004 22 657 682 2-s2.0-2542432162 10.1146/annurev.immunol.22.012703.104731 (Pubitemid 38680437)
142. Sebastião A. M., Ribeiro J. A., Adenosine receptors and the central nervous system. Handbook of Experimental Pharmacology 2009 193 471 534 2-s2.0-70349309933 10.1007/978-3-540-89615-9-16
143. Stone T. W., Ceruti S., Abbracchio M. P., Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handbook of Experimental Pharmacology 2009 193 535 587 2-s2.0-70349331090 10.1007/978-3-540-89615-9-17
144. Canas P. M., Porciúncula L. O., Cunha G. M. A., Silva C. G., Machado N. J., Oliveira J. M. A., Oliveira C. R., Cunha R. A., Adenosine A 2 A receptor blockade prevents synaptotoxicity and memory dysfunction caused by β -amyloid peptides via p38 mitogen-activated protein kinase pathway. Journal of Neuroscience 2009 29 47 14741 14751 2-s2.0-72449208698 10.1523/JNEUROSCI.3728-09.2009
145. 1 receptor activation to A 2 A receptor blockade. Purinergic Signalling 2005 1 2 111 134 2-s2.0-16344372309 10.1007/s11302-005-0649-1 (Pubitemid 40466898)
146. Rebola N., Lujan R., Cunha R. A., Mulle C., Adenosine A 2 A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron 2008 57 1 121 134 2-s2.0-37549021899 10.1016/j.neuron.2007.11. 023
147. Fredholm B. B., Chen J.-F., Cunha R. A., Svenningsson P., Vaugeois J.-M., Adenosine and brain function. International Review of Neurobiology 2005 63 191 270 2-s2.0-17844403763 10.1016/S0074-7742(05)63007-3 (Pubitemid 43631262)
148. Gomes C. V., Kaster M. P., Tomé A. R., Agostinho P. M., Cunha R. A., Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochimica et Biophysica Acta 2011 1808 5 1380 1399 2-s2.0-79953220421 10.1016/j.bbamem.2010.12.001
149. 1 and A 2 A adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Research 1995 705 1-2 79 84 2-s2.0-0029417320 10.1016/0006-8993(95)01153-6
150. Jones P. A., Smith R. A., Stone T. W., Protection against kainate-induced excitotoxicity by adenosine A 2 A receptor agonists and antagonists. Neuroscience 1998 85 1 229 237 2-s2.0-0031969591 10.1016/S0306-4522(97)00613-1 (Pubitemid 28228426)
151. Talukder M. A. H., Morrison R. R., Ledent C., Mustafa S. J., Endogenous adenosine increases coronary flow by activation of both A 2 A and A 2 B receptors in mice. Journal of Cardiovascular Pharmacology 2003 41 4 562 570 2-s2.0-0037379872 10.1097/00005344-200304000-00008 (Pubitemid 36373793)
152. 2 receptors. European Journal of Immunology 2003 33 11 3127 3135 2-s2.0-0242559051 10.1002/eji.200323566 (Pubitemid 37428345)
153. Zhu Y., Liu L., Peng X., Ding X., Yang G., Li T., Role of adenosine A 2 A receptor in organ-specific vascular reactivity following hemorrhagic shock in rats. Journal of Surgical Research 2013 184 2 951 958
154. Arosio B., Viazzoli C., Mastronardi L., Bilotta C., Vergani C., Bergamaschini L., Adenosine A {2A} receptor expression in peripheral blood mononuclear cells of patients with mild cognitive impairment. Journal of Alzheimer's Disease 2010 20 4 991 996 2-s2.0-77954547258 10.3233/JAD-2010-090814
155. Gussago C., Arosio B., Casati M., Ferri E., Gualandris F., Tedone E., Nicolini P., Rossi P. D., Abbate C., Mari D., Different adenosine A 2 A receptor expression in peripheral cells from elderly patients with vascular dementia and alzheimer's disease. Journal of Alzheimer's Disease 2014 40 1 45 49 10.3233/JAD-131652
156. Marques S., Batalha V. L., Lopes L. V., Outeiro T. F., Modulating alzheimer's disease through caffeine: a putative link to epigenetics. Journal of Alzheimer's Disease 2011 24 supplement 2 161 171 2-s2.0-79955649058 10.3233/JAD-2011-110032
157. Helmy A. A., Abdel Naseer M. M., El Shafie S., Nada M. A. F., Role of interleukin 6 and alpha-globulins in differentiating Alzheimer and vascular dementias. Neurodegenerative Diseases 2012 9 2 81 86 2-s2.0-84856754551 10.1159/000329568
158. Simonsen A. H., Hagnelius N. O., Waldemar G., Nilsson T. K., McGuire J., Protein markers for the differential diagnosis of vascular dementia and Alzheimer's disease. International Journal of Proteomics 2012 2012 8 824024 10.1155/2012/824024
159. Chen J.-F., Huang Z., Ma J., Zhu J., Moratalla R., Standaert D., Moskowitz M. A., Fink J. S., Schwarzschild M. A., A 2 A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. Journal of Neuroscience 1999 19 21 9192 9200 2-s2.0-0033232779 (Pubitemid 30228071)
160. Yang Z. J., Wang B., Kwansa H., Heitmiller K. D., Hong G., Carter E. L., Jamrogowicz J. L., Larson A. C., Martin L. J., Koehler R. C., Adenosine A 2 A receptor contributes to ischemic brain damage in newborn piglet. Journal of Cerebral Blood Flow & Metabolism 2013 33 10 1612 1620
161. Pelligrino D. A., Xu H.-L., Vetri F., Caffeine and the control of cerebral hemodynamics. Journal of Alzheimer's Disease 2010 20 supplement 1 S51 S62 2-s2.0-77956212388 10.3233/JAD-2010-091261
162. Govoni S., Gasparini L., Racchi M., Trabucchi M., Peripheral cells as an investigational tool for Alzheimer's disease. Life Sciences 1996 59 5-6 461 468 2-s2.0-0030567753 10.1016/0024-3205(96)00325-6 (Pubitemid 26246901)
163. Centonze D., Battistini L., Maccarrone M., The endocannabinoid system in peripheral lymphocytes as a mirror of neuroinflammatory diseases. Current Pharmaceutical Design 2008 14 23 2370 2342 2-s2.0-52949125632 10.2174/138161208785740018